Soluble syndecan-1 levels in different plasma cell dyscrasias and in different stages of multiple myeloma.
We measured serum levels of syndecan-1 in patients with multiple myeloma (MM), solitary plasmocytoma and monoclonal gammopathy of undetermined significance (MGUS). We then studied serum syndecan-1 levels in MM patients stratified by the Durie-Salmon staging system and the correlation of syndecan-1 levels with well known independent prognostic factors of MM.